Research and Development
GBI Biomanufacturing HQ
1850 NW 69th Ave, Plantation, FL 33313
Listing Price: $10,260,000
Investment Overview
GBI Biomanufacturing Headquarters, located at 1850 NW 69th Avenue in Plantation, Florida, a 38,000 square-foot biologics manufacturing and life sciences facility in Broward County. The property is fully leased to GBI Biomanufacturing, Inc., a contract development and manufacturing organization (CDMO) specializing in mammalian cell culture development and cGMP biologics production.
The asset is secured by a triple-net lease with approximately seven years of remaining term through May 31, 2033, providing stable cash flow while minimizing landlord responsibilities, as the tenant is responsible for taxes, insurance, operating expenses, and maintenance. The lease also includes 2.6 percent annual rent escalations, providing consistent income growth throughout the remaining primary lease term.
The facility supports highly specialized biologics manufacturing operations requiring tailored laboratory buildouts, advanced mechanical systems, and pharmaceutical-grade production infrastructure. GBI has invested approximately $26 million into the facility, demonstrating significant tenant commitment while creating substantial barriers to relocation.
The investment also offers a clear value-add component through the lease renewal structure. Upon the first renewal option, rent resets to 90 percent of prevailing market rent, representing over 40 percent mark-to-market rent upside based on current underwriting. This structure provides the ability to significantly increase income at the end of the primary term, producing a projected 9.84 percent cap rate in year seven.
Additionally, the property benefits from Florida’s recently enacted stem cell legislation, which allows certain regenerative treatments to be offered within the state and has helped increase demand for stem cell manufacturing capacity. GBI has indicated the expanded facility will support the production of up to one million stem cell units annually, positioning the asset within a rapidly growing segment of the biotechnology sector.
Investment Highlights
- TRIPLE-NET LEASE – SEVEN YEARS REMAINING: 100% leased to GBI Biomanufacturing through May 2033 with minimal landlord responsibilities.
- VALUE-ADD OPPORTUNITY: Value-Add Opportunity - 9.84% Pro Forma Cap Rate.
- NEW FLORIDA STEM CELL LEGISLATION: Recent state law enabling regenerative treatments supports increased demand for stem cell manufacturing capacity.
- LIFE SCIENCES MANUFACTURING FACILITY: Specialized laboratory and biologics production infrastructure designed for pharmaceutical-grade operations.
- STRATEGIC BROWARD COUNTY LOCATION: Central South Florida location with access to Sunrise Boulevard, Interstate 95, Florida's Turnpike, and Fort Lauderdale-Hollywood International Airport.
- MARK-TO-MARKET OPPORTUNITY: The tenant currently pays below-market rent of approximately $16.20/SF, compared to an estimated current market rent of $24.00/SF.
- TENANT INVESTMENT IN FACILITY: Significant capital invested into specialized cGMP biologics manufacturing infrastructure, creating high relocation barriers.
Exclusively Listed By
Listing Price: $10,260,000
Investment Highlights
- TRIPLE-NET LEASE – SEVEN YEARS REMAINING: 100% leased to GBI Biomanufacturing through May 2033 with minimal landlord responsibilities.
- VALUE-ADD OPPORTUNITY: Value-Add Opportunity - 9.84% Pro Forma Cap Rate.
- NEW FLORIDA STEM CELL LEGISLATION: Recent state law enabling regenerative treatments supports increased demand for stem cell manufacturing capacity.
- LIFE SCIENCES MANUFACTURING FACILITY: Specialized laboratory and biologics production infrastructure designed for pharmaceutical-grade operations.
- STRATEGIC BROWARD COUNTY LOCATION: Central South Florida location with access to Sunrise Boulevard, Interstate 95, Florida's Turnpike, and Fort Lauderdale-Hollywood International Airport.
- MARK-TO-MARKET OPPORTUNITY: The tenant currently pays below-market rent of approximately $16.20/SF, compared to an estimated current market rent of $24.00/SF.
- TENANT INVESTMENT IN FACILITY: Significant capital invested into specialized cGMP biologics manufacturing infrastructure, creating high relocation barriers.
Investment Overview
GBI Biomanufacturing Headquarters, located at 1850 NW 69th Avenue in Plantation, Florida, a 38,000 square-foot biologics manufacturing and life sciences facility in Broward County. The property is fully leased to GBI Biomanufacturing, Inc., a contract development and manufacturing organization (CDMO) specializing in mammalian cell culture development and cGMP biologics production. The asset is secured by a triple-net lease with approximately seven years of remaining term through May 31, 2033, providing stable cash flow while minimizing landlord responsibilities, as the tenant is responsible for taxes, insurance, operating expenses, and maintenance. The lease also includes 2.6 percent annual rent escalations, providing consistent income growth throughout the remaining primary lease term. The facility supports highly specialized biologics manufacturing operations requiring tailored laboratory buildouts, advanced mechanical systems, and pharmaceutical-grade production infrastructure. GBI has invested approximately $26 million into the facility, demonstrating significant tenant commitment while creating substantial barriers to relocation. The investment also offers a clear value-add component through the lease renewal structure. Upon the first renewal option, rent resets to 90 percent of prevailing market rent, representing over 40 percent mark-to-market rent upside based on current underwriting. This structure provides the ability to significantly increase income at the end of the primary term, producing a projected 9.84 percent cap rate in year seven. Additionally, the property benefits from Florida’s recently enacted stem cell legislation, which allows certain regenerative treatments to be offered within the state and has helped increase demand for stem cell manufacturing capacity. GBI has indicated the expanded facility will support the production of up to one million stem cell units annually, positioning the asset within a rapidly growing segment of the biotechnology sector.
Exclusively Listed By